Healios K K : Notice Concerning Reduction of Capital Stock and Capital Reserves and Appropriation of Surplus
February 24, 2022 at 01:12 am EST
Share
February 24, 2022
Company Name:
HEALIOS K.K.
Representative:
Hardy TS Kagimoto, Chairman & CEO
(TSE Mothers Code: 4593)
Contact:
Richard Kincaid, Executive Officer CFO
(TEL: 03-5962-9440)
Notice Concerning Reduction of Capital Stock and Capital Reserves
and Appropriation of Surplus
HEALIOS K.K. ("Healios") announces that its Board of Directors, at a meeting held on February 24, 2022, resolved to propose an agenda "Reduction of Capital Stock and Capital Reserves and Appropriation of Surplus" at the 11th General Shareholders Meeting to be held on March 25, 2022 as follows.
1. Purpose of reduction of capital stock and capital reserves and appropriation of surplus
In accordance with Article 447, paragraph 1 of the Companies Act and Article 448, Paragraph 1 of the Companies Act, we would like to reduce capital stock and capital reserves, to transfer them to other capital surplus, and then to transfer other capital surplus after the increase to retained earnings under Article 452 of the Companies Act for the purpose of eliminating carry-forward losses and reducing tax burden as per the below.
Note that this proposal does not change the number of outstanding shares and will only reduce the amount of capital stock and capital reserves, so it will not affect the number of shares held by shareholders. In addition, since there is no change in the net asset value of Healios, there is no change in the net asset value per share.
2. Details of reduction of capital stock
(1) Amount of capital stock to be reduced
2,736,468,729 yen as of December 31, 2021 out of 6,178,692,870 yen for the total amount of capital stock, to be reduced to 3,442,224,141 yen.
If the stock options issued by Healios are exercised by the effective date, the amount of the capital
1
and the amount of the capital after the decrease will fluctuate.
(2) Method to reduce capital stock
The amount of capital stock will be reduced and transferred to other capital surplus.
3. Details of reduction of capital reserves
(1) Amount of capital reserves to be reduced
2,736,468,729 yen as of December 31, 2021 out of 6,177,692,871 yen for the total amount of capital reserves, to be reduced to 3,441,224,142 yen.
If the stock options issued by Healios are exercised by the effective date, the amount of the capital reserves and the amount of the capital reserves after the decrease will fluctuate.
(2) Method to reduce capital reserves
The amount of capital reserves will be reduced and transferred to other capital surplus.
4. Details of appropriation of surplus
In accordance with the Article 452 of the Companies Act, Healios will cover the deficiency by transferring other capital surplus to retained earnings, subject to the effect of the reduction in the amount of capital stock and capital reserves as described above. As a result, the amount of retained earnings after the transfer will be 0 yen.
Other capital surplus to be reduced and the amount thereof Other capital surplus 5,472,937,458 yen
Retained earnings to be increased and the amount thereof Retained earnings 5,472,937,458 yen
5. Dates (planned)
(1) Date of resolution of the Board of Directors
February 24, 2022
(2) Resolution date of the General Meeting of
March 25, 2022
Shareholders
(3) Final description date of creditor's objection
March 25, 2022
(4) Effective date of reduction in capital stock,
March 31, 2022
capital reserves and appropriation of
surplus
6. Future outlook
The reduction of capital stock and capital reserves and the appropriation of surplus mentioned above are merely transfers of account titles within the net assets section, and there is no change
2
of the amount of Healios's net assets and there is no effect on Healios's business performance.
3
Attachments
Original Link
Original Document
Permalink
Disclaimer
Healios KK published this content on 24 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 February 2022 06:11:08 UTC.
HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.